Dogwood Bets Big on Non-Opioid Pain Drug as Key Trial Nears Finish

ATLANTA, GA – March 18, 2026 – As the search for effective, non-addictive pain therapies intensifies, development-stage biotech company Dogwood Therapeutics (Nasdaq: DWTX) announced significant progress in its mission to treat debilitating nerve pain. The company reported promising interim clinical data for its lead candidate, Halneuron®, and confirmed it has secured the necessary funding to carry it through a critical trial readout expected later this year.

The announcement, part of its fourth quarter and full year 2025 financial results, positions Dogwood at a crucial juncture. With its Phase 2b study for Halneuron® now more than half enrolled, the company is on track to deliver top-line results in the third quarter of 2026, a milestone that could validate its novel approach to a condition that currently has no approved treatments.

“The Company continues to execute at a high level, including recruitment of 143 patients in our ongoing Halneuron® Phase 2b trial, commencement of a Phase 2b extension trial and the recent execution of a financing to provide us with operational runway through the Phase 2b final data readout later this year,” said Greg Duncan, Chief Executive Officer of Dogwood Therapeutics, in the company's press release.

A New Hope for Chemotherapy-Induced Pain

At the heart of Dogwood's efforts is the fight against chemotherapy-induced neuropathic pain (CINP), a severe side effect affecting up to one-third of all patients undergoing cancer treatment. This condition, caused by nerve damage from neurotoxic chemotherapy agents like taxanes and platinum-based drugs, manifests as chronic pain, tingling, and numbness, primarily in the hands and feet. The pain can be so debilitating that it forces patients to reduce or even discontinue life-saving cancer therapies, profoundly impacting their quality of life and treatment outcomes.

Despite its prevalence and severity, there are currently no therapies specifically approved by the Food and Drug Administration (FDA) for CINP. This leaves patients and clinicians to rely on off-label use of general chronic pain medications, such as gabapentin and duloxetine, which often provide limited relief and come with their own side effects. This significant unmet need has created a potential $1.5 billion market for an effective treatment.

Dogwood's Halneuron® aims to fill this void. The drug has already received Fast Track designation from the FDA, a status reserved for therapies that treat serious conditions and demonstrate the potential to address an unmet medical need. This designation facilitates more frequent communication with the agency and can expedite the development and review process.

Promising Signs from the Clinic

The company’s optimism is fueled by recent findings from its ongoing HALT-CINP Phase 2b study. An interim analysis conducted in December 2025 on data from 97 patients yielded encouraging results. According to the company, an independent statistical review committee concluded that Halneuron® was demonstrating a “separation from placebo,” meaning patients receiving the drug showed greater pain improvement than those receiving a placebo.

This finding is particularly noteworthy given the challenging patient population. The subjects in the analysis had been suffering from CINP for an average of five years, and two-thirds were already taking other chronic pain medications. The ability to show a positive signal in such a treatment-resistant group suggests a potentially robust therapeutic effect. Furthermore, the trial has exhibited a very low dropout rate of around 4%, indicating the treatment is well-tolerated by patients.

Based on this interim data, the independent committee recommended increasing the trial's sample size to between 210 and 240 patients. While this extends the recruitment timeline slightly, it is a strategic move designed to ensure the final results have a high degree of statistical power—between 80% and 85%—to definitively prove Halneuron®'s effectiveness in pain reduction.

The Science of Silencing Pain

Halneuron® works by targeting a specific mechanism in the nervous system known as the NaV 1.7 voltage-gated sodium channel. This channel, found predominantly in pain-sensing peripheral neurons, acts as an amplifier for pain signals. Its critical role in pain transmission was discovered through human genetics; individuals born with a non-functional NaV 1.7 channel are unable to feel pain, while those with overactive channels suffer from extreme pain disorders.

This makes NaV 1.7 a highly sought-after target for a new generation of non-opioid analgesics. However, the path to a successful NaV 1.7 inhibitor has been fraught with challenges. Many previous attempts by other companies have failed because their drug candidates were not specific enough, leading to off-target effects and an unacceptable therapeutic window.

Dogwood Therapeutics believes Halneuron® overcomes this hurdle with its “inherent specificity and potency.” By precisely targeting the NaV 1.7 channel, the drug is designed to block pain signals effectively at lower doses, potentially minimizing the side effects that have plagued earlier programs.

The High Cost of Innovation

Bringing such a novel therapy to market is a high-risk, high-reward endeavor, a reality reflected in Dogwood's financial statements. The company reported a net loss of $35.5 million for 2025, a substantial increase from the $12.9 million loss in 2024. This was driven primarily by a surge in research and development expenses, which climbed to $21.8 million for the year as the Halneuron® trial advanced.

These figures underscore the immense capital required for late-stage clinical development. To fuel these efforts, Dogwood announced in January 2026 that it had completed a financing deal for up to $26.9 million, with an initial $11.4 million in net proceeds already received. This infusion of capital is critical, providing the company with an operational runway through the end of 2026, past the all-important data readout for the Phase 2b study.

With cash and equivalents at $6.5 million at the end of 2025, the new funding ensures that the company's fate now rests squarely on the strength of its clinical data. A positive outcome in the third quarter would likely serve as a major catalyst, attracting further investment or partnership opportunities needed for a larger, more expensive Phase 3 trial and eventual commercialization. Beyond Halneuron®, Dogwood is also developing SP16 IV, a candidate aimed at repairing nerve damage, suggesting a broader, long-term strategy to address neuropathic disorders.